Tuesday, July 11, 2023
Presented by Seema Kumar, CEO, Cure
Thank you for joining us on LinkedIn Live on Tuesday, July 11th for our discussion with physician-scientist-executive, Judith Absalon, about her experience at Pfizer and GSK as a clinical trialist both during COVID pandemic and currently.
Where: Virtual audience only on LinkedIn Live
Topic: A fireside chat with Judith Absalon MD, MPH, FIDSA, on her experience as a Principal Investigator for Pfizer. Hosted by Seema Kumar, CEO, Cure.
Dr. Judith Absalon is an Adult Infectious Diseases physician and experienced clinical researcher with more than 20 years of experience. She has spent the last 15 years contributing to the development of antiviral drugs and vaccines. Dr. Absalon joined Glaxo Smith Kline in October 2021 where she serves as Vice President and Clinical Sciences Disease Area Lead of Infectious Diseases & Virology. Prior to joining GSK, Dr. Absalon was a Senior Medical Director in Vaccines Research & Development at Pfizer, Inc. where she led several vaccine clinical development programs. In 2020, in response to the COVID-19 pandemic, Dr. Absalon was a core team member on the mRNA COVID-19 vaccine clinical development program where she contributed to the licensure of Comirnaty® both for Emergency Use Authorization and full licensure. She has previously held positions in Virology Clinical Research at Bristol Myers Squibb, the Department of Epidemiology, Mailman School of Public Health at Columbia University, and Division of Infectious Diseases, Harlem Hospital Center, College of Physicians & Surgeons, Columbia University. Throughout her career Dr. Absalon has prioritized the health of women. She has conducted research focused on prevention of HIV and other sexually transmitted infections in women, HIV treatment in pregnant women as well clinical development of novel maternal vaccines.
Seema joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.